Article Contents ::
- 1 Details About Generic Salt :: Megestro
- 2 Main Medicine Class::
- 3 (meh-JESS-trole ASS-uh-TATE) Megace Suspension 40 mg/mL Tablets 20 mg Tablets 40 mg Apo-Megestrol Linmegestrol Megace OS Nu-Megestrol class: Progestin Indications Palliative treatment of advanced inoperable, recurrent, or metastatic carcinoma of breast or endometrium. Appetite stimulation in HIV-related cachexia. Contraindications Hypersensitivity to progestins; as diagnostic test for pregnancy. Route/Dosage Breast Cancer ADULTS: PO 40 mg qid. Endometrial Cancer ADULTS: PO 40 to 320 mg/day in divided doses. Interactions None well documented. Lab Test Interferences Endocrine, coagulation (increased amounts of coagulation factors), thyroid and LFT results may be affected by progestins; may alter metyrapone test results; may decrease glucose tolerance. Adverse Reactions CARDIOVASCULAR: Hypertension; thromboembolic phenomena, including thrombophlebitis and pulmonary embolism. CNS: Insomnia; fatigue. DERMATOLOGIC: Rash; alopecia; mild acne. GI: Abdominal pain or discomfort; nausea; vomiting. GU: Breakthrough bleeding; change in menstrual flow; changes in cervical erosion and secretions; impotence. HEPATIC: Cholestatic jaundice. RESPIRATORY: Dyspnea. OTHER: Breast tenderness; masculinization of female fetus; edema; weight changes; decreased libido; tumor flare; carpal tunnel syndrome; increased appetite. Precautions Pregnancy: Category D. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Fluid retention: Use with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac or renal dysfunction, epilepsy). Hepatic impairment: Use with caution and with close monitoring in patients with liver dysfunction. Mental depression: Carefully observe patients with history of depression. Ophthalmic effects: Discontinue if there are any sudden changes in vision, sudden onset of proptosis, diplopia, migraine, papilledema, or retinal vascular lesions. Thromboembolic disease: Use with caution in patients with history of thromboembolic disease. PATIENT CARE CONSIDERATIONS Administration/Storage Store in dry, cool place at room temperature. Assessment/Interventions Obtain complete patient history, including drug history and any known allergies. Note history of thromboembolic disease. Assess results of baseline liver, thyroid, and coagulation tests prior to initiation of therapy and routinely during therapy. Monitor blood glucose in patients with diabetes. Monitor patient’s mental status: affect, mood, depression, behavioral changes. Notify health care provider if any of these symptoms occur: pain in calves accompanied by swelling, warmth and redness; severe sudden headache; visual disturbances; numbness in extremities; signs of depression; signs of liver dysfunction (eg, dark urine, jaundice); breakthrough bleeding. Patient/Family Education Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug. Explain potential significance of breakthrough bleeding, irregular menstrual cycles, and possible lack of menstrual cycle. Tell patient to notify health care provider of heavy or continuous menstrual flow. Encourage patients with diabetes to monitor blood glucose more frequently until effect on diabetes control has been determined. Instruct patient to report these symptoms to health care provider: pain in calves of legs with redness, warmth and swelling; sudden severe headache; visual disturbances; numbness in extremities; dyspnea; chest pain; edema; jaundice; dark urine; clay-colored stools. Caution patient to avoid exposure to sunlight and other sources of ultraviolet light and to use sunscreen or wear protective clothing to avoid photosensitivity reaction. Medicscientist Drug Facts
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Megestro
Main Medicine Class::
Drugs Class ::
(meh-JESS-trole ASS-uh-TATE) |
Megace |
Suspension |
40 mg/mL |
Tablets |
20 mg |
Tablets |
40 mg |
Apo-Megestrol |
Linmegestrol |
Megace OS |
Nu-Megestrol |
class: Progestin |
Indications for Drugs ::
Indications Palliative treatment of advanced inoperable, recurrent, or metastatic carcinoma of breast or endometrium.
Appetite stimulation in HIV-related cachexia.
Drug Dose ::
Route/Dosage
Breast Cancer
ADULTS: PO 40 mg qid.
Endometrial Cancer
ADULTS: PO 40 to 320 mg/day in divided doses.
Contraindication ::
Contraindications Hypersensitivity to progestins; as diagnostic test for pregnancy.
Drug Precautions ::
Precautions
Pregnancy: Category D. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Fluid retention: Use with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac or renal dysfunction, epilepsy). Hepatic impairment: Use with caution and with close monitoring in patients with liver dysfunction. Mental depression: Carefully observe patients with history of depression. Ophthalmic effects: Discontinue if there are any sudden changes in vision, sudden onset of proptosis, diplopia, migraine, papilledema, or retinal vascular lesions. Thromboembolic disease: Use with caution in patients with history of thromboembolic disease.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CARDIOVASCULAR: Hypertension; thromboembolic phenomena, including thrombophlebitis and pulmonary embolism. CNS: Insomnia; fatigue. DERMATOLOGIC: Rash; alopecia; mild acne. GI: Abdominal pain or discomfort; nausea; vomiting. GU: Breakthrough bleeding; change in menstrual flow; changes in cervical erosion and secretions; impotence. HEPATIC: Cholestatic jaundice. RESPIRATORY: Dyspnea. OTHER: Breast tenderness; masculinization of female fetus; edema; weight changes; decreased libido; tumor flare; carpal tunnel syndrome; increased appetite.
Drug Mode of Action ::
(meh-JESS-trole ASS-uh-TATE) |
Megace |
Suspension |
40 mg/mL |
Tablets |
20 mg |
Tablets |
40 mg |
Apo-Megestrol |
Linmegestrol |
Megace OS |
Nu-Megestrol |
class: Progestin |
Drug Interactions ::
Interactions None well documented.
Drug Assesment ::
Assessment/Interventions
- Obtain complete patient history, including drug history and any known allergies. Note history of thromboembolic disease.
- Assess results of baseline liver, thyroid, and coagulation tests prior to initiation of therapy and routinely during therapy.
- Monitor blood glucose in patients with diabetes.
- Monitor patient’s mental status: affect, mood, depression, behavioral changes.
- Notify health care provider if any of these symptoms occur: pain in calves accompanied by swelling, warmth and redness; severe sudden headache; visual disturbances; numbness in extremities; signs of depression; signs of liver dysfunction (eg, dark urine, jaundice); breakthrough bleeding.
Drug Storage/Management ::
Administration/Storage
- Store in dry, cool place at room temperature.
Drug Notes ::
Patient/Family Education
- Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
- Explain potential significance of breakthrough bleeding, irregular menstrual cycles, and possible lack of menstrual cycle. Tell patient to notify health care provider of heavy or continuous menstrual flow.
- Encourage patients with diabetes to monitor blood glucose more frequently until effect on diabetes control has been determined.
- Instruct patient to report these symptoms to health care provider: pain in calves of legs with redness, warmth and swelling; sudden severe headache; visual disturbances; numbness in extremities; dyspnea; chest pain; edema; jaundice; dark urine; clay-colored stools.
- Caution patient to avoid exposure to sunlight and other sources of ultraviolet light and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
Medicscientist Drug Facts